Arcturus Therapeutics Holdings Inc. (ARCT) stock
ARCTNasdaqPharmaceutical PreparationsFiscal year ends December 31
Financials through Q3 FY2026, quarter ended Sep 30, 2026Last filing: 10-Q on Nov 5, 2026Score 9/303% below fair value
$8.36−0.08 (-0.95%)
Close on Nov 13, 2026Market cap $237.62MP/E –Yield –
Arcturus Therapeutics r&d expenses
Research and development expenses are spending on new products and technology.
Arcturus Therapeutics's R&D Expenses for the twelve months ending Sep 30, 2026 was $80.52M, down 38.8% year over year. For fiscal 2025 it was $112.21M, down 42.5% from the year before. The highest annual figure on record is $195.16M in fiscal 2024.
Annual r&d expenses
| Period | Period end | Value | Change |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | $112.21M | -42.5% |
| FY2024 | Dec 31, 2024 | $195.16M | +1.6% |
| FY2023 | Dec 31, 2023 | $192.13M | +30.0% |
| FY2022 | Dec 31, 2022 | $147.75M | -15.0% |
| FY2021 | Dec 31, 2021 | $173.76M | +200.4% |
| FY2020 | Dec 31, 2020 | $57.85M | +72.0% |
| FY2019 | Dec 31, 2019 | $33.64M | +98.1% |
| FY2018 | Dec 31, 2018 | $16.98M | – |
Quarterly r&d expenses
Change is against the same quarter a year earlier.
| Period | Period end | Value | Change |
|---|---|---|---|
| Q3 FY2026 | Sep 30, 2026 | $17.00M | -26.9% |
| Q2 FY2026 | Jun 30, 2026 | $17.52M | -40.8% |
| Q1 FY2026 | Mar 31, 2026 | $21.53M | -38.3% |
| Q4 FY2025 | Dec 31, 2025 | $24.48M | -44.1% |
| Q3 FY2025 | Sep 30, 2025 | $23.27M | -40.6% |
| Q2 FY2025 | Jun 30, 2025 | $29.58M | -49.6% |
| Q1 FY2025 | Mar 31, 2025 | $34.89M | -34.9% |
| Q4 FY2024 | Dec 31, 2024 | $43.78M | +19.6% |
| Q3 FY2024 | Sep 30, 2024 | $39.13M | -23.4% |
| Q2 FY2024 | Jun 30, 2024 | $58.67M | +11.4% |
| Q1 FY2024 | Mar 31, 2024 | $53.57M | +3.5% |
| Q4 FY2023 | Dec 31, 2023 | $36.62M | +35.7% |
| Q3 FY2023 | Sep 30, 2023 | $51.08M | +35.5% |
| Q2 FY2023 | Jun 30, 2023 | $52.67M | +37.9% |
| Q1 FY2023 | Mar 31, 2023 | $51.77M | +15.3% |
| Q4 FY2022 | Dec 31, 2022 | $26.98M | -17.3% |
| Q3 FY2022 | Sep 30, 2022 | $37.69M | -17.0% |
| Q2 FY2022 | Jun 30, 2022 | $38.19M | -16.4% |
| Q1 FY2022 | Mar 31, 2022 | $44.89M | -10.3% |
| Q4 FY2021 | Dec 31, 2021 | $32.63M | +34.4% |
| Q3 FY2021 | Sep 30, 2021 | $45.40M | +156.5% |
| Q2 FY2021 | Jun 30, 2021 | $45.68M | +475.0% |
| Q1 FY2021 | Mar 31, 2021 | $50.05M | +532.2% |
| Q4 FY2020 | Dec 31, 2020 | $24.29M | +102.5% |
| Q3 FY2020 | Sep 30, 2020 | $17.70M | +150.9% |
| Q2 FY2020 | Jun 30, 2020 | $7.94M | +9.3% |
| Q1 FY2020 | Mar 31, 2020 | $7.92M | +8.1% |
| Q4 FY2019 | Dec 31, 2019 | $11.99M | +147.5% |
| Q3 FY2019 | Sep 30, 2019 | $7.05M | +77.7% |
| Q2 FY2019 | Jun 30, 2019 | $7.27M | +72.0% |
| Q1 FY2019 | Mar 31, 2019 | $7.32M | – |
| Q4 FY2018 | Dec 31, 2018 | $4.85M | – |
| Q3 FY2018 | Sep 30, 2018 | $3.97M | – |
| Q2 FY2018 | Jun 30, 2018 | $4.23M | – |
See a number that looks wrong?